Wound Healing Peptides

Promotes wound closure and healing

Primary Use

Wound healing peptides accelerate the body's natural repair process by promoting new blood vessel formation, increasing collagen deposition, and recruiting repair cells to the injury site. BPC-157 is the most widely researched in this category, with extensive animal data showing accelerated healing of skin wounds, burns, muscle tears, tendon injuries, and even intestinal damage. TB-500 (thymosin beta-4) complements it by promoting cell migration through actin regulation.

GHK-Cu also belongs here as a wound healing peptide: it signals fibroblasts and immune cells to remodel damaged tissue and has been used in clinical wound care products. The appeal of these peptides is that they target the biological bottlenecks in healing (blood supply, cell recruitment, collagen production) rather than just managing symptoms.

This page collects every peptide on PeptideWiki tagged for wound healing. Browse individual profiles for mechanisms, dosing protocols, and safety data.

Peptides (5)

Frequently Asked Questions

BPC-157 promotes angiogenesis (new blood vessel formation) at the wound site, which increases the delivery of oxygen, nutrients, and immune cells. It also upregulates growth factor receptors. TB-500 regulates actin, a structural protein that cells use to migrate toward the wound. GHK-Cu activates genes involved in collagen synthesis, antioxidant defense, and tissue remodeling. Each targets a different bottleneck in the repair process, which is why they are often combined.

Animal studies with BPC-157 show accelerated healing of surgical incisions, anastomoses (reconnected tissue), and post-surgical adhesions. TB-500 has been studied in the context of tissue repair after injury. While these results are promising, controlled human surgical recovery trials are limited. Some practitioners use them off-label for post-surgical support, but this should be discussed with a surgeon since promoting blood vessel growth near a surgical site has both potential benefits and theoretical risks.

BPC-157 appears effective both locally (injected near the wound) and systemically (injected in the abdomen). Research suggests it accumulates at sites of damage regardless of injection location. GHK-Cu is available as both injectable and topical formulations; topical application directly to skin wounds is effective for surface injuries. TB-500 is typically administered systemically. For deep tissue injuries, systemic administration is standard. For surface wounds, topical GHK-Cu may be sufficient.

Surface wounds and minor injuries often show visible improvement within 3-7 days. Deeper tissue injuries, tendon damage, and ligament tears typically require 2-6 weeks of consistent use. Chronic wounds that have stalled in the healing process may take longer. The timeline depends heavily on the injury type, severity, blood supply to the area, and overall health. Tendons and ligaments heal slower than muscle because they have less blood flow.

Related Primary Use Tags